AI assistant
Vitrolife — Board/Management Information 2021
Dec 1, 2021
2989_rns_2021-12-01_39892350-6744-43ee-861f-69ac579b6a57.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Press Release December 1, 2021 Gothenburg, Sweden
Vitrolife announces changes to the executive management team after the acquisition of Igenomix
As announced on 30 November, 2021, Vitrolife AB (publ) completed the acquisition of Igenomix, as a result, changes will be made to the executive management team effective 1 January, 2022.
The executive management team will from 1 January, 2022, consist of:
Thomas Axelsson, President and Chief Executive Officer
Group Functions:
Francisco Jiménez, SVP Strategy & Corporate Development Karin Koritz Russberg, SVP HR & Sustainability Carlos Simón, Chief Scientific Officer
Patrik Tolf, Chief Financial Officer
Business Areas: Claus Bisgaard, SVP Vitrolife Technology Ricardo Capella, SVP Igenomix Maria Forss, SVP Vitrolife Consumables
Business Functions: Rickard Ericsson, SVP Vitrolife Sales & Marketing Francisco Rodriguez, SVP Igenomix Affiliates
Gothenburg, December 1, 2021 VITROLIFE AB (publ) Thomas Axelsson, CEO
Contact persons: Thomas Axelsson, CEO, tel: +46 31 721 80 01 Mikael Engblom, CFO, tel: +46 31 721 80 14
Vitrolife is an international medical device and genetic services Group. Vitrolife develops, produces and markets products for reproductive health together with services that provide personalised genetic information to improve clinical practices in infertility, women's health and rare diseases. Headquartered in Gothenburg, Sweden, the Group currently employs approximately 1,200 people worldwide. Its products, services and solutions are available in more than 110 markets through a network of subsidiaries and distributors. The Group has a wide-ranging experience in the fertility field with an advanced research capacity. The Vitrolife share is listed on NASDAQ Stockholm.
_____________________________________________________________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: [email protected]. Website: www.vitrolife.com
The information was submitted for publication, through the agency of the contact persons set out above, at 1:00 pm CET on December 1, 2021.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.